Clopidogrel: How good is it and how does it work?

Current Cardiology Reports

Volumn 6, Issue 4, 2004, Pages 264-268

  Santa Cruz, Richard A ^b   Steinhubl, Steven R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; THROMBOCYTE RECEPTOR; THROMBOXANE A2; TICLOPIDINE; WARFARIN;

ANGIOGENESIS; ARTICLE; BLEEDING; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENDOTHELIUM INJURY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; NEUTROPENIA; OUTCOMES RESEARCH; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PLASMA HALF LIFE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS;

EID: 5444270696     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0074-z     Document Type: Article

References (24)

1. Antithrombotic Trialists C: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [erratum appears in BMJ 2002 324:141]. BMJ 2002, 324:71-86.
2. Geiger J, Brich J, Honig-Liedl P, et al.: Specific impairment of human platelet P2YAC ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999, 19:2007-2011.
3. Mills DCB, Puri R, Hu C-J, et al.: Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992, 12:430-436.
4. Hollopeter G, Jantzen H-M, Vincent D, et al.: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2000, 409:202-207.
5. Bhatt DL, Topol EJ: Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003, 2:15-28.
6. Savi P, Pereeillo JM, Uzabriaga MF, et al.: Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000, 84:891-896.
7. Steinhubl S, Berger P: What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? Am Heart J 2003, 145:971-978.
8. Sasaki Y, Hoshi M, Akazawa C, et al.: Selective expression of Gi/o-coupled ATP receptor P2Y12 in microglia in rat brain Glia 2003, 44:242-250.
9. Simon J, Filippov AK, Goransson S, et al.: Characterization and channel coupling of the P2Y(12) nucleotide receptor of brain capillary endothelial cells. J Biol Chem 2002, 277 31390-31400.
10. Muller I, Seyfarth M, Rudiger S, et al.: Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001, 85:92-93.
11. Boneu B, Destelle G, on behalf of the study group: Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996, 76:939-943.
12. Bossavy J-P, Thalamas C, Sagnard L, et al.: A double-blind randomised comparison of combined aspirin and ticlopidine versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood 1998, 92:1518-1525.
13. Cadroy Y, Bossavy JP, Thalamas C, et al.: Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000, 101:2823-2828.
14. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348:1329-1339.
15. Bhatt D, Chew D, Hirsch A, et al.: Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001, 103:363-368.
16. Bhatt DL, Marso SP, Hirsch AT, et al.: Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus Am J Cardiol 2002, 90:625-627.
17. Ringleb PA, Bhatt DL, Hirsch AT, et al.: Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004, 35:528-32.
18. Yusuf S, Mehta SR, Zhao F, et al.: Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003, 107:966-972.
19. Yende S, Wunderink RG: Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001, 29 2271-2275.
20. Peters RJ, Mehta SR, Fox KA, et al.: Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003, 108: 1682-1687.
21. Mehta S, Yusuf S, Peters R, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undrgoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001, 358:527-533.
22. Steinhubl SR, Berger PB, Mann III JT, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 2002, 288:2411-2420.
23. Steinhubl S, Darrah S, Brennan D, et al.: Optimal duration of pretreatment with clopidogrel prior to PCI: data from the CREDO trial. Abstract presented at the American Heart Association Scientific Sessions. Orlando, FL: November 9-12, 2003.
24. Braunwald E, Antman E, Beasley J, et al.: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina http://www.acc.org/clinical/guidelines/unstable/unstable.pdf